½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓëÔ·¢ÐÔ¹ÇÖÊÊèËɵÄÏà¹ØÐÔ¡ï
èï¾ü࣬³ÂÏþÁÁ£¬Ô¬°Ùʤ£¬ÖÜÕþ¸Ù
¿ÎÌâ±³¾°£º½µ¸ÆËØÊÇÈËÌåµ÷½Ú¸Æ´úлºÍ¹Çת»»µÄÖØÒª¼¤ËØ£¬½µ¸ÆËØÊÜÌåÔÚ¹Ç÷ÀÖÐÖ÷Òª·Ö²¼ÔÚÆÆ¹Çϸ°û¼°ÆäǰÌåϸ°ûÉÏ£¬µ÷½ÚÌåÄڹǴúлºÍά³Ö¡£±¾ÊÔÑéͨ¹ý¾ÛºÏøÁ´·´Ó¦£ÏÞÖÆÐÔ³¤¶È¶à̬ÐÔ¼¼Êõ·ÖÎö½º¶«°ëµººº×åÈËȺ½µ¸ÆËØÊÜÌå¸÷»ùÒòÐÍ·Ö²¼ÆµÂÊ£¬½øÒ»²½Ì½ÌÖ¸÷»ùÒòÐÍÓë¹ÇÃܶȵĹØÏµ¼°Æä¶à̬ÐÔÓë¹ÇÖÊÊèËÉÐÔ¹ÇÕÛµÄÏà¹ØÐÔ¡£
Ó¦ÓÃÒªµã£ºÊÔÑé½á¹ûÌáʾÈËȺ½µ¸ÆËØÊÜÌå»ùÒòÐÍÆµÂÊ·Ö²¼¾ù·ûºÏHardy-Weinberg ¶¨ÂÉ¡£½º¶«°ëµºÊÜÊÔÈËȺ»ùÒòÐÍÆµÂÊ·Ö²¼ÒÀ´ÎΪCCÐÍ£¬CTÐÍ£¬TTÐÍ¡£½µ¸ÆËØÊÜÌåC1377T»ùÒò¶à̬ÐÔ¿ÉÄܳÉΪ½º¶«°ëµººº×åÅ®ÐÔ·¢Éú¹ÇÖÊÊèËÉΣÏÕÐÔµÄÒÅ´«±êÖ¾¡£
Ïà¹ØÁ´½Ó£º¶Ô½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓë¹ÇÃܶȹØÏµµÄÑо¿ÔÚ¹ú¼ÊÉÏ¿ªÊ¼ÒýÆðÖØÊÓ¡£¾¡¹Ü¹úÄÚÍâ½øÐÐÁË´óÁ¿µÄÏà¹ØÐÔÑо¿£¬µ«ÊÇÓÉÓÚ´æÔÚÖÖ×å¼°»·¾³µÈ¶à·½ÃæµÄÓ°Ï죬½µ¸ÆËØÊÜÌå»ùÒò¼°Æä¶à̬ÐÔÔÚ¹ÇÖÊÊèËɵIJ¡Àí»úÖÆÖÐËùÆðµÄ×÷Óò¢Î´È¡µÃ¹²Ê¶¡£ÿÿÿ
Çൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¼¹ÖùÍâ¿Æ£¬É½¶«Ê¡ÇൺÊÐ
266003
èï¾üΰ¡ï£¬ÄУ¬1975ÄêÉú£¬É½¶«Ê¡½ºÖÝÊÐÈË£¬ºº×壬Çൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¹Ç¿ÆÔÚ¶Á˶ʿ£¬×¡ÔºÒ½Ê¦£¬Ö÷Òª´ÓÊ»ùÒò¶à̬ÐÔÓë¹ÇÖÊÊèËÉÏà¹ØÐÔµÄÑо¿¡£
ljw_003@hotmail.com
ͨѶ×÷Õߣº³ÂÏþÁÁ£¬½ÌÊÚ£¬Ö÷ÈÎҽʦ£¬Ë¶Ê¿Éúµ¼Ê¦£¬Çൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¼¹ÖùÍâ¿Æ£¬É½¶«Ê¡ÇൺÊÐ 266003
ÕªÒª
Ä¿µÄ:¹ÇÖÊÊèËÉÊǶà»ùÒòµ÷¿Ø¼²²¡£¬·åÖµ¹ÇÁ¿´ïµ½ºÍ¹ÇÁ¿¶ªÊ§¾ùÊÜÒÅ´«ÒòËØÓ°Ïì¡£¹Û²ìɽ¶«°ëµºµØÇøºº×åÈËȺ½µ¸ÆËØÊÜÌåAlu-¢ñ»ùÒò¶à̬ÐÔ¸÷»ùÒòÐÍÆµÂʼ°ÆäÓë¹ÇÖÊÊèËɵĹØÏµ£¬Ì½ÌÖÔ·¢ÐÔ¹ÇÖÊÊèËÉÖ¢µÄÒÅ´«Ò׸ÐÒòËØ¡£
·½·¨£ºÊÔÑéÓÚ2005-06/2007-06ÔÚÇൺ´óѧҽѧԺ¸½ÊôÒ½ÔºÖÐÐÄʵÑéÊÒÍê³É¡£¢ÙÊÔÑé¶ÔÏó£ºÑ¡È¡332Ãû³¤ÆÚ¾ÓסÔÚɽ¶«°ëµºµØÇøÎÞÇ×Ôµ¹ØÏµµÄºº×åÈËȺ£¬ÄÉÈë±ê×¼£º½¡¿µÃÅÕï²éÌåÈËÔ±¡¢Ô·¢ÐÔ¹ÇÖÊÊèËÉÖ¢¼°Ô·¢ÐÔ¹ÇÖÊÊèËÉÖ¢ËùÖ¹ÇÕÛ»¼Õߣ»»¼Õß¶ÔÊÔÑéÖªÇéͬÒâ¡£Åųý±ê×¼£º¸÷Ö̷ּ¢ÐÔ¹ÇÖÊÊèËÉÖ¢£»Ó°Ïì¹Ç´úлÏà¹Ø¼²²¡Ê·£»·þÓÃÓ°Ïì¹Ç´úлҩÎïµÈ¡£ÆäÖйÇÖÊÊèËɺϲ¢¹ÇÕÛ75Àý×÷Ϊ¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ×飬Óà257Àý¾¹ý¹ÇÃܶȲⶨȷ¶¨¹ÇÁ¿£¬°´¹ÇÖÊÊèËÉÕï¶Ï±ê×¼£¨¹ÇÃܶȲⶨֵ±ÈͬÐÔ±ð·åÖµ¹ÇÃܶȾùÖµ½µµÍ2.5¸ö±ê×¼²î£©·ÖΪ¹ÇÁ¿Õý³£×飨n =201£©¼°¹ÇÖÊÊèËÉ×飨n =56£©¡£¢ÚÊÔÑé·½·¨£ºÓ¦ÓþۺÏøÁ´·´Ó¦ÏÞÖÆÐÔÆ¬¶Î³¤¶È¶à̬ÐÔ·ÖÎö¼¼Êõ²â¶¨257Ãûɽ¶«°ëµººº×å³ÉÄêÈ˺Í75Ãû¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ»¼Õß½µ¸ÆËØÊÜÌå»ùÒòÐÍ£¬ÓÃË«ÄÜXÉäÏßÎüÊÕ·¨²â¶¨Ñü×µ¡¢¹É¹Ç¾±¡¢´Ö¡¼ä¡¢Ward¡¯sÈý½ÇºÍ´óת×ÓÇøµÈ²¿Î»µÄ¹ÇÃܶÈÖµ¡£
½á¹û£ºÄÉÈëÊÜÊÔÕß332ÈË£¬¾ù½øÈë½á¹û·ÖÎö¡£¢Ù±¾ÊÔÑéÈËȺ½µ¸ÆËØÊÜÌå»ùÒòÐÍÆµÂÊ·Ö²¼¾ù·ûºÏHardy-Weinberg ¶¨ÂÉ(¦Ö2=0.47£¬P =0.493)¡£»ùÒòÐÍÆµÂÊ·Ö²¼ÒÀ´ÎΪCCÐÍÕ¼89.5%£¬CTÐÍÕ¼10.5%£¬TTÐÍÕ¼0%¡£¢ÚÄêÁäÓ벻ͬ²¿Î»¹ÇÃܶÈÖµÖ®¼ä³Ê¸ºÏà¹Ø£¨P < 0.01£©£¬ÌåÖÊÁ¿Ö¸ÊýÓë¹ÇÃܶÈÖµÖ®¼ä³ÊÕýÏà¹Ø£¨P < 0.01£©£¬ÔÚ½«ÄêÁäºÍÌåÖÊÁ¿Ö¸Êý½øÐÐУÕýºó·¢ÏÖÅ®ÐÔCC»ùÒòÐͽÏCT»ùÒòÐÍÔÚward¡¯sÈý½ÇÇøÓнϸߵĹÇÃܶȣ¨P < 0.05)£¬¹ÇÁ¿Õý³£×é¸÷»ùÒòÐÍÓë¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ×éÖ®¼ä²îÒìÎÞÏÔÖøÐÔÒâÒ壨P > 0.05)¡£
½áÂÛ£ºÉ½¶«°ëµººº×åÅ®ÐÔ½µ¸ÆËØÊÜÌå»ùÒòÐÍÓë¹ÇÃܶÈÖ®¼ä´æÔÚÒ»¶¨¹ØÁª£¬½µ¸ÆËØÊÜÌåC1377T»ùÒò¶à̬ÐÔ¿ÉÄܳÉΪ½º¶«°ëµººº×åÅ®ÐÔ·¢Éú¹ÇÖÊÊèËÉΣÏÕÐÔµÄÒÅ´«±êÖ¾¡£
¹Ø¼ü´Ê£º½µ¸ÆËØÊÜÌ壻»ùÒò¶à̬ÐÔ£»¹ÇÃܶȣ»¹ÇÖÊÊèËÉ£»×éÖ¯¹¹½¨
èï¾ü࣬³ÂÏþÁÁ£¬Ô¬°Ùʤ£¬ÖÜÕþ¸Ù.½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓëÔ·¢ÐÔ¹ÇÖÊÊèËɵÄÏà¹ØÐÔ[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(7):1243-1246 [www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1243(ps).pdf]
ÖÐͼ·ÖÀàºÅ:R681.4
ÎÄÏ×±êʶÂë:B
ÎÄÕ±àºÅ:1673-8225
(2008)07-01243-04
ÊÕ¸åÈÕÆÚ£º2007-09-07 ÐÞ»ØÈÕÆÚ£º2007-10-26 (07-50-9-4894/WL¡¤A£©
Association between calcitonin receptor gene polymorphism and primary osteoporosis
Abstract
AIM:Osteoporosis is a polygenic disease, and the peak bone mass and bone mass loss are significantly determined by genetic factors. The study determined the genotype frequencies of calcitonin receptor Alu ¢ñ gene polymorphism and its association with osteoporosis in Shandong peninsula Han populations, so as to explore the predisposing factor for osteoporosis in heredity.
METHODS: The experiment was conducted in the central laboratory of Affiliated Hospital of Qingdao Medical College from June 2005 to June 2007. ¢Ù332 Han people from unrelated families who lived in Shandong peninsula for many years were selected. Those with healthy physical examination personnel from health clinic, primary osteoporosis and primary osteoporotic fracture were enrolled, and the informed consents were obtained from all the participants. All people with various secondary osteoporosis, bone metabolism disease, and drugs that had influence on bone metabolism were excluded. People with osteoporosis complicated by fracture served as osteoporotic fracture group (n =75), and the rest were divided into normal bone mass group (n =201) and osteoporosis group (n =56) according to the body mass (bone densitometry was 2.5 standard deviation lower than peak bone density of the same sex). ¢ÚAlu ¢ñ polymorphism of calcitonin receptor gene was tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 257 adults and 75 patients with osteoporotic fracture. The bone mineral density of lumbar spine (L2-4), intertroch, femoral neck, Ward's triangle area and greater trochanter were measured by dual-energy X-ray absorptiometry (DEXA).
RESULTS: 332 subjects were all involved in the result analysis. ¢ÙThe frequencies distribution of Alu ¢ñ alleles and genotypes in this cohort were accorded with Hardy-Weinberg equilibrium (¦Ö2 =0.47, P =0.493). The frequency distribution of genotypes CC, CT and TT were 89.5%, 10.5% and 0%. ¢ÚAge showed significant negative correlation with bone mineral density (P < 0.01), and body mass index had significant positive correlation with bone mineral density (P < 0.01). The bone mineral density in Ward's triangle of women with CC genotype was significant higher compared with CT genotype (P < 0.05) after the body mass index and age were corrected. There was no significant difference between osteoporotic fracture group and normal control group (P > 0.05).
CONCLUSION: There is a possible correlation between calcitonin receptor gene polymorphisms and bone mineral density in Han female of Shandong peninsula. C1377T gene polymorphism may act as the genetic marker in predicting the risk factor for osteoporosis.
Luan JW, Chen XL, Yuan BS, Zhou ZG.Association between calcitonin receptor gene polymorphism and primary osteoporosis.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(7):1243-1246(China)
[www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1243(ps).pdf]
0 ÒýÑÔ
¹ÇÖÊÊèËÉÖ¢ÊÇ×î³£¼ûµÄ¹Ç´úл¼²²¡£¬¼Òϵ[1]¼°Ë«°ûÌ¥Ñо¿±íÃ÷¹ÇÖÊÊèËÉÖ¢ÊǶà»ùÒòµ÷¿Ø¡¢Ç¿ÒÅ´«ÐԵļ²²¡¡£×Ô1994ÄêMorrisonµÈ[2]Ê״νÒʾάÉúËØDÊÜÌåÓë¹ÇÃܶÈÓйØÁªÒÔÀ´£¬Ó°Ïì¹ÇÃܶȵĻùÒò¶à̬ÐÔÓë¹ÇÃܶȼ°¹ÇÕÛ¹ØÏµµÄÑо¿Öð½¥ÉîÈ룬Èç¢ñÐͽºÔ»ùÒò[3]¡¢µÍÃܶÈÖ¬µ°°×ÊÜÌåÏà¹Øµ°°×»ùÒò[4]¼°´óÂéËØÊÜÌå»ùÒò[5-6]µÈ¡£
½µ¸ÆËØÊÇÈËÌåµ÷½Ú¸Æ´úлºÍ¹Çת»»µÄÖØÒª¼¤ËØ£¬½µ¸ÆËØÊÜÌåÔÚ¹Ç÷ÀÖÐÖ÷Òª·Ö²¼ÔÚÆÆ¹Çϸ°û¼°ÆäǰÌåϸ°ûÉÏ£¬µ÷½ÚÌåÄڹǴúлºÍά³Ö¡£¶Ô½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓë¹ÇÃܶȹØÏµµÄÑо¿ÔÚ¹ú¼ÊÉÏ¿ªÊ¼ÒýÆðÖØÊÓ¡£¾¡¹Ü¹úÄÚÍâ½øÐÐÁË´óÁ¿µÄÏà¹ØÐÔÑо¿£¬µ«ÊÇÓÉÓÚ´æÔÚÖÖ×å¼°»·¾³µÈ¶à·½ÃæµÄÓ°Ï죬½µ¸ÆËØÊÜÌå»ùÒò¼°Æä¶à̬ÐÔÔÚ¹ÇÖÊÊèËɵIJ¡Àí»úÖÆÖÐËùÆðµÄ×÷Óò¢Î´È¡µÃ¹²Ê¶¡£
±¾ÊÔÑéͨ¹ý¾ÛºÏøÁ´·´Ó¦-ÏÞÖÆÐÔ³¤¶È¶à̬ÐÔ¼¼Êõ·ÖÎö½º¶«°ëµººº×åÈËȺ½µ¸ÆËØÊÜÌå¸÷»ùÒòÐÍ·Ö²¼ÆµÂÊ£¬½øÒ»²½Ì½ÌÖ¸÷»ùÒòÐÍÓë¹ÇÃܶȵĹØÏµ¼°Æä¶à̬ÐÔÓë¹ÇÖÊÊèËÉÐÔ¹ÇÕÛµÄÏà¹ØÐÔ¡£
1 ¶ÔÏóºÍ·½·¨
Éè¼Æ£ºËæ»ú¶ÔÕչ۲졣
µ¥Î»£ºÇൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¡£
¶ÔÏó£ºÊÔÑéÓÚ2005-06/2007-06ÔÚÇൺ´óѧҽѧԺ¸½ÊôÒ½ÔºÖÐÐÄʵÑéÊÒÍê³É¡£Ñ¡È¡³¤ÆÚ¾ÓסÔÚɽ¶«°ëµºµØÇøÎÞÇ×Ôµ¹ØÏµµÄºº×åÈËȺ£¬ÈëÑ¡¶ÔÏó¾ù½øÐÐÏêϸµÄÌå¼ì¡¢¼ì²é¸ÎÉö¹¦ÄÜ¡¢Ñª¼Ø¡¢ÄÆ¡¢ÂÈ¡¢¸ÆºÍÁ×ˮƽ£»¼××´ÏÙ¹¦ÄÜ¡¢Ñª¼××´ÅÔÏÙ¼¤ËØË®Æ½¡£²¢¾µ÷²éÎʾíÅųýÓ°Ïì¹Ç´úлµÄÒ©ÎÈç´Æ¼¤ËØ¡¢½µ¸ÆËØ¡¢¶þì¢ËáÑΡ¢Î¬ÉúËØD ºÍ·ú»¯ÎïµÈ¡£ÄÉÈë±ê×¼£º½¡¿µÃÅÕï²éÌåÈËÔ±¡¢Ô·¢ÐÔ¹ÇÖÊÊèËÉÖ¢¼°Ô·¢ÐÔ¹ÇÖÊÊèËÉÖ¢ËùÖ¹ÇÕÛ£»»¼Õß¶ÔÊÔÑéÖªÇéͬÒâ¡£Åųý±ê×¼£º¸÷Ö̷ּ¢ÐÔ¹ÇÖÊÊèËÉÖ¢£»Ó°Ïì¹Ç´úлÏà¹Ø¼²²¡Ê·£»·þÓÃÓ°Ïì¹Ç´úлҩÎïµÈ¡£Ñ¡Ôñ¹ÇÖÊÊèËɺϲ¢¹ÇÕÛ75Àý×÷Ϊ¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ×飬257Àý¾¹ý¹ÇÃܶȲⶨȷ¶¨¹ÇÁ¿£¬°´¹ÇÖÊÊèËÉÕï¶Ï±ê×¼£¨¹ÇÃܶȲⶨֵ±ÈͬÐÔ±ð·åÖµ¹ÇÃܶȾùÖµ½µµÍ2.5¸ö±ê×¼²î£©·ÖΪ¹ÇÁ¿Õý³£×飨n =201£©¼°¹ÇÖÊÊèËÉ×飨n =56£©¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÊÔÑéÉè¼Æ¡¢¸ÉԤʵʩ¼°ÆÀ¹À¾ùΪµÚÒ»¡¢¶þ×÷Õߣ¬ÊܹýÕý¹æÅàѵ£¬²ÉÓÃä·¨ÆÀ¹À¡£
·½·¨£º
¸ÉÔ¤´ëÊ©£ºËùÓÐÊÔÑé¶ÔÏó¾ù³éÈ¡Ç峿¿Õ¸¹ÍâÖܾ²ÂöѪ5 mL£¬ÆäÖÐ3 mL ÖÃÓÚÆÕͨÊÔ¹ÜÖÐÒԲⶨѪ¸Æ¡¢Áס¢¼îÐÔÁ×Ëáø¡¢ÑªÌǵÈÉú»¯Ö¸±ê£¬ÁíÍâ2 mL ÖÃÓÚÎÞ¾úÎÞøµÄEDTA¿¹ÄýµÄÊÔ¹ÜÖÐ-20 ¡æ ±£´æ¡£227ÃûÊÜÊÔÕß¾¹ýË«ÄÜXÉäÏß¹ÇÃܶÈÒÇ£¨GE LUNAR DPX-NT£¬USA£©¼ì²âÑü×µ¡¢¹É¹Ç¾±¡¢ward¡¯sÈý½Ç¡¢´óת×Ó¡¢¹É¹Ç¸ÉµÈ²¿Î»¹ÇÃܶÈÖµ¡£²ÉÓÃpromega¹«Ë¾ÌṩµÄDNA³éÈ¡ºÐ£¨A1120£©³éÌåÍâÖÜѪDNA¡£ÒÔ2 ¦ÌL DNAΪģ°åͨ¹ýPCRÀ©ÔöÄ¿µÄƬ¶Î¡£ÒýÎï[10]·Ö±ðΪÉÏÓΣºTTC AGT GGA ACC AGC GTT GG£»ÏÂÓΣºCTC AGT GTA CAC GAT ACT GTG(ÓÉÉϺ£ÉúÎ﹤³Ì¼¼ÊõÓÐÏÞ¹«Ë¾ºÏ³É)¡£·´Ó¦Ìõ¼þ£º94 ¡æ Ô¤±äÐÔ3 min£¬94 ¡æ ±äÐÔ45 s£¬57 ¡æ ÍË»ð45 s£¬72 ¡æ ÑÓÉì40 s£¬35¸öÑ»·£¬72 ¡æ ÔÙÑÓÉì10 min¡£À©Ôö²úÎïÆ¬¶ÏΪ228 bp¡£¾1.5%µÄÇíÖ¬ÌÇÄý½ºµçӾȷÈÏÀ©Ôö½á¹ûºó£¬¼ÌÒÔALU-¢ñÏÞÖÆÐÔÄÚÇÐø37 ¡æ øÇÐPCR²úÎï16 h¡£×îºóÓÃ3%ÇíÖ¬ÌÇÄý½ºµçÓ¾¼ø¶¨Ã¸ÇвúÎïÆ¬¶Ï¡£ä廯ÒÒ¶§È¾É«£¬×ÏÍâµÆÏ¹۲졣ÎÞALU-¢ñøÇÐλµãµÄCC´¿ºÏ×ÓÏÔʾ228 bp 1Ìõ´ø£¬ÓÐALU-¢ñøÇÐλµãµÄTT´¿ºÏ×ÓÏÔʾ120 bp¡¢108 bp 2Ìõ´ø¡£CTÐÍÔÓºÏ×ÓÏÔʾ228 bp¡¢120 bp¡¢108 bp 3Ìõ´ø¡£
Ö÷Òª¹Û²ìÖ¸±ê£º¸÷×é½µ¸ÆËØÊÜÌå»ùÒòÐÍ·Ö²¼ÆµÂʼ°¶ÔÓ¦¹ÇÃܶÈÖµ¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷Õß²ÉÓûùÒò¼ÆÊý·¨·Ö±ðͳ¼Æ¸÷×é»ùÒòÐͺ͵Èλ»ùÒòƵÂÊ£¬Êý¾Ý¾Hardy-weinberg ƽºâ¼ìÑéºó£¬ÓÃSPSS 11.5ͳ¼ÆÈí¼þ·ÖÎö£¬¼ÆÁ¿×ÊÁÏÒÔ_x¡Às±íʾ£¬ÓÃPearsonÏà¹Ø·ÖÎöÄêÁä¼°ÌåÖÊÁ¿Ö¸ÊýÓë¹ÇÃܶȵĹØÏµ£¬ÓÃз½²î·ÖÎöµÄ·½·¨±È½ÏÄêÁä¡¢Éí¸ß¡¢ÌåÖÊÁ¿Ð£Õýºó¸÷²¿Î»¹ÇÃܶȺͽµ¸ÆËØÊÜÌå»ùÒòÐÍÖ®¼äµÄ¹ØÏµ£»ÆµÂÊ·Ö²¼¼°¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ×黼ÕßÓë¹ÇÁ¿Õý³£ÈËȺ»ùÒòÐÍ·ÖÎö²ÉÓæÖ2¼ìÑé¡£P < 0.05Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒ壬P < 0.01Ϊ²îÒìÓзdz£ÏÔÖøÐÔÒâÒå¡£
2 ½á¹û
2.1 ²ÎÓëÕßÊýÁ¿·ÖÎö ÄÉÈ볤ÆÚ¾ÓסÔÚɽ¶«°ëµºµØÇøÎÞÇ×Ôµ¹ØÏµµÄºº×åÊÜÊÔÕß332ÈË£¬¾ù½øÈë½á¹û·ÖÎö£¬ÎÞÍÑÂä¡£
2.2 ½µ¸ÆËØÊÜÌå»ùÒòÐÍ·Ö²¼ ½µ¸ÆËØÊÜÌå»ùÒòALU-¢ñøÇÐλµã¶à̬ÐÔÈ·¶¨Îª£ºC±íʾ²»´æÔÚÏàӦøÇÐλµã£¬T±íʾ´æÔÚÏàӦøÇÐλµã£¬Òò¶ø¶ÔÓ¦µÄ»ùÒòÐÍÓÐ3ÖÖ£ºCCÐÍ£¨ÖÕ²úÎïÖ»ÓÐ228 bp 1Ìõ´ø£©£»CTÐÍ£¨ÔÓºÏ×Ó£¬ÖÕ²úÎïΪ228 bp¡¢120 bp¡¢108 bp 3Ìõ´ø£©£¨¼ûͼ1£©¡£Ñ¡È¡15·ÝPCR²úÎï²âÐò£¬¾ù·ûºÏÉÏÊöøÇнá¹û¡£»ùÒòÐÍÓëµÈλ»ùÒò·Ö²¼ÆµÂʼû±í1¡£¾HWEÈí¼þ¼ìÑé½µ¸ÆËØÊÜÌå¸÷»ùÒòÐͼ°µÈλ»ùÒòƵÂÊ·Ö²¼£¬¾ù·ûºÏHardy- Weinberg ¶¨ÂÉ(¦Ö2=0.47£¬P =0.493)¡£

2.3 ÊÜÊÔÕßÌåÖÊÁ¿Ö¸Êý¡¢ÄêÁäÓë¸÷²¿Î»¹ÇÃܶȵÄÏà¹ØÐÔ·ÖÎö ¼û±í2¡£
¶Ô¸÷²¿Î»¹ÇÃܶÈÖµÓëÄêÁä¡¢ÌåÖÊÁ¿Ö¸ÊýµÄ»Ø¹é·ÖÎö·¢ÏÖ£¬ÄêÁäÓë¸÷²¿Î»µÄ¹ÇÃܶȳʸºÏà¹Ø£¨P < 0.01£©£»ÌåÖÊÁ¿Ö¸ÊýÓë¹ÇÃܶÈÖµ³ÊÕýÏà¹Ø£¨P < 0.01£©¡£ËµÃ÷ÄêÁäÓëÌåÖÊÁ¿Ö¸Êý¾ùÓ°Ï첻ͬ²¿Î»¹ÇÃܶÈÖµ¡£
2.4 ÊÜÊÔÕßÄêÁä¡¢ÌåÖÊÁ¿Ö¸Êý½ÏÕýºó¸÷²¿Î»¹ÇÃܶÈÖµÓë½µ¸ÆËØ»ùÒòÐ͵ÄÏà¹ØÐÔ ¼û±í3¡£
ÔÚ·Ö±ð¶ÔÄêÁä¡¢ÌåÖÊÁ¿¡¢ÄêÁäÓëÌåÖÊÁ¿½øÐнÏÕýºó£¬ward¡¯s Èý½Ç²¿Î»µÄ¹ÇÃܶÈÖµÓë¸÷»ùÒòÐÍÏà¹Ø£¬Å®ÐÔCC»ùÒòÐͽÏCT»ùÒòÐÍÔÚward¡¯sÈý½ÇÇøÓнϸߵĹÇÃܶȣ¨P < 0.05£©£¬²»Í¬²¿Î»µÄCCÐ͹ÇÃܶÈÖµ¾ù´óÓÚCT ÐÍ¡£
2.5 ¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ×éºÍ¹ÇÁ¿Õý³£×é»ùÒòƵÂÊ±È½Ï ¼û±í4¡£
¶Ô75Ãû¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÓë¹ÇÃܶÈÕý³£ÊÜÊÔ¸öÌåµÄ»ùÒòÐÍÆµÂʽøÐзÖÎö£¬ÈÏΪ¹ÇÖÊÊèËÉÐÔ¹ÇÕ۵ķ¢ÉúÔÚ²»Í¬»ùÒòÐͼä²îÒìÎÞÏÔÖøÐÔÒâÒ壨P > 0.05£©¡£
3 ÌÖÂÛ
½µ¸ÆËØÊÜÌå»ùÒò¶¨Î»ÓÚÈËȾɫÌå7q21.3[7]¡£ÔÚɨÃèÈËÀཱུ¸ÆËØÊÜÌå»ùÒòʱ·¢ÏÖ11¸ö¶à̬ÐÔλµã£¬ÆäÖÐ10¸öλµã´æÔÚµ¥ºËÜÕËá¶à̬ÐÔ(SNP)Í»±ä£¬ÆäÖÐÁ½¸öSNPÔÚ»ùÒò±àÂëÇøÄÚ£¬¶øÕâÆäÖÐÒ»¸öλµã´æÔÚ°±»ùËáµÄÍ»±ä[8]¡£ÏÖÖ¤Ã÷ÆäºËÜÕËáÐòÁÐ1 377´¦µÄCÍ»±äΪT£¬µ¼ÖÂÏàÓ¦µÄµ°°×½á¹¹Öи¬°±Ëá(CCG)Í»±äΪÁÁ°±Ëá(CTG)£¬´Ó¶øÊ¹½µ¸ÆËØÊÜÌå»ùÒò²úÉúCC(´¿¸¬°±Ëá)¡¢TT(´¿ÁÁ°±Ëá)¡¢CT (¸¬°±Ëá¡¢ÁÁ°±ËáÔÓ½»ÐÍ) 3ÖÖ»ùÒòÐÍ¡£¸Ãµ¥ºËÜÕËáÍ»±äÓ°Ïìµ½ÆäÓëÅäÌåµÄ½áºÏ²¢¸Ä±äÁËÊÜÌåÐźÅתµ¼µÄÌØÐÔ£¬´Ó¶øÓ°ÏìÁ˰Ðϸ°û¶Ô½µ¸ÆËصķ´Ó¦¡£
1997ÄêNakamuraµÈ[9]¶Ô152Ãû16~43ËêÈÕ±¾Å®ÐÔ½øÐÐÑо¿£¬½âÊÍÁËÔÚÈÕ±¾ÈËȺÖÐAlu-¢ñ½µ¸ÆËØÊÜÌåµÄ¶à̬ÐÔ£¬ÈÏΪ¹ÇÃܶÈÔÚ3¸ö»ùÒòÐͼäÎÞ²îÒì¡£1998ÄêMasiµÈ[10]·ÖÎöÁË201Ãû47~76Ëê¾ø¾ºóµÄÒâ´óÀû¸¾Å®ÕâÖÖ¶à̬ÐÔ·Ö²¼£¬½á¹ûÓëÈÕ±¾ÈËÏà·´£ºCC»ùÒòÐÍÓëTT»ùÒòÐÍÏà±ÈÔÚÑü×µÓÐÃ÷ÏԸߵĹÇÃܶȡ£TsaiµÈ[11]¶Ô167Ãû¾ø¾ºóÅ®ÐÔÑо¿Öз¢ÏÖTTÐÍÓëµÍ¹ÇÁ¿Óйء£BandresµÈ[12]ºÍ²¨À¼µÄDrewsµÈ[13]µÄÑо¿Óë¸ß¼ÓË÷ÈËȺÏàËÆ£¬ÓëÑÇÖÞÈ˲»Í¬¡£¹úÄÚ¶Ôºº×åÈ˸÷»ùÒòÐͶԹÇÃܶÈÓ°ÏìµÄÑо¿Òà´æÔÚ·ÖÆç£¬2002ÄêÕÂÕñÁÖµÈ[14]¶Ô±±¾©µØÇøºº×帾ٵÄÑо¿Öз¢ÏÖ£¬½µ¸ÆËØÊÜÌå»ùÒòÐÍÓë·åÖµ¹ÇÁ¿µÄ´ïµ½ºÍά³ÖÓйأ¬µ«Æäͬʱָ³ö£¬½µ¸ÆËØÊÜÌå»ùÒòÐͲ»ÄÜ×÷ΪԤ²âÖйúºº×帾Ů·¢Éú¹ÇÖÊÊèËÉΣÏÕÐÔµÄÒÅ´«Ñ§±êÖ¾¡£´ÞѧÎĵÈ[15]¶Ô303Ãûɽ¶«¸¾Å®Ñо¿½á¹ûÏÔʾ»ùÒò·Ö²¼ÆµÂÊCC¡¢TT¡¢CTÐÍ·Ö±ðΪ100%¡¢0¡¢0¡£ÍõçùµÈ[16]¶Ô²â¶¨ÏĺÓÏØ²Ø×åÈËȺµÄ½µ¸ÆËØÊÜÌå»ùÒòµ¥ºËÜÕËá¶à̬ÐÔ£¬·¢ÏÖ²Ø×åµÄ½µ¸ÆËØÊÜÌå»ùÒòÐÍͨ¹ýÓ°Ïì·åÖµ¹ÇÁ¿µÄ»ñµÃ³ÉΪӰÏì¹ÇÖÊÊèËÉ·¢ÉúµÄΣÏÕÒòËØ¡£ÐíÃ÷»ÛµÈ[17]ÔÚ¶ÔºÓ±±ºº×åÅ®ÐÔµÄÑо¿Öз¢ÏÖCTÐÍÑü×µ¹ÇÃܶÈÓнµµÍµÄÇ÷ÊÆ¡£Àî¶«·çµÈ[18]¶Ô¹ãÖݵØÇøºº×å¾ø¾ºóÅ®ÐÔÑо¿Öз¢ÏÖ3ÖÖ»ùÒòÐ͵ĹÇÃܶÈÖµÖ®¼ä²îÒìÎÞÏÔÖøÐÔÒâÒå¡£Àî¶«·çµÈ[19]ÓÖ¶ÔÄêÁä¡Ý65Ëê¹ãÖݵØÇøºº×åÄÐÐÔ½øÐÐÑо¿£¬ÈÏΪ½µ¸ÆËØ»ùÒòC1377T»ùÒò¶à̬ÐÔÉв»ÄÜ×÷ΪԤ²âºº×åÀÏÄêÄÐÐÔ·¢Éú¹ÇÖÊÊèËÉΣÏÕÐÔµÄÒÅ´«±êÖ¾¡£ÕâЩÑо¿½øÒ»²½Ö¤ÊµÁ˽µ¸ÆËØÊÜÌåµÄ»ùÒò¶à̬ÐÔ·Ö²¼ÆµÂÊ´æÔÚÖÖ×å²îÒìÐÔ£¬Òѱ¨µÀµÄ¸ß¼ÓË÷È˺ÍÒâ´óÀûÈËÓëÈÕ±¾È˺ÍÖйúºº×åÈ˵ĻùÒòÐÍ·Ö²¼ÏÔÖø²»Í¬¡£
±¾ÊÔÑé±íÃ÷ɽ¶«°ëµº½µ¸ÆËØÊÜÌåC1377T¶à̬ÐÔ¸÷»ùÒòÐÍ·Ö²¼ÆµÂÊÓë±±¾©¡¢ÉϺ£¡¢¹ãÖݵȵػùÒòÐÍ·Ö²¼ÆµÂÊÏàËÆ£¬ÓëÌ©°²µØÇø¼°¸ß¼ÓË÷ÈËÖÖ·Ö²¼ÆµÂÊÏÔÖø²»Í¬¡£ÔÚ¸÷»ùÒòÐÍÓë¹ÇÃܶȹØÏµ·½Ã棬CTÐ͸÷²¿Î»¹ÇÃܶÈÖµ¾ùСÓÚCC»ùÒòÐÍ£¬ÄêÁäÓë¹ÇÃܶÈÖµ³ÊÏÔÖø¸ºÏà¹Ø£¬Ëæ×ÅÄêÁäµÄÔö¼Ó£¬¹ÇÃܶÈÖð½¥½µµÍ£¬¶øÌåÖÊÁ¿Ö¸ÊýÓë¹ÇÃܶȳÊÏÔÖøÕýÏà¹Ø¡£±¾ÊÔÑéÔÚ¶Ô¸÷²¿Î»¹ÇÃܶÈÖµ·ÖÎöʱÔËÓÃз½²î·ÖÎö£¬½«ÕâЩӰÏìÒòËØÆëͬºó·Ö±ð¶Ô²»Í¬ÐÔ±ðÊÜÊÔÕß½øÐзÖÎö£¬·¢ÏÖÅ®ÐÔÊÜÊÔÕßCTÐÍÔÚward¡¯sÈý½Ç¹ÇÃܶÈÖµÃ÷ÏÔµÍÓÚCCÐÍ£¬²îÒì¾ßÓÐÏÔÖøÐÔÒâÒ壨P < 0.05£©£»¶øÄÐÐÔ×éµÄÑо¿È´Î´·¢ÏÖ´æÔÚ¹ØÁª¡£ÕâÒ»½á¹ûÓëMasiµÈ[10]ºÍTsaiµÈ[11]Ñо¿½á¹ûÏàËÆ£¬±íÃ÷ɽ¶«°ëµººº×åÅ®ÐÔCT»ùÒòÐÍward¡¯sÈý½ÇÇøÓò¾ßÓнϵ͹ÇÃܶȣ¬CT»ùÒòÐÍ¿ÉÄܳÉΪ½º¶«°ëµººº×帾Ů·¢Éú¹ÇÖÊÊèËÉΣÏÕÐÔµÄÒÅ´«±êÖ¾¡£¹ÇÖÊÊèËɵÄÖ±½Óºó¹ûÊǹÇÕÛ£¬ËùÒÔ¹ÇÖÊÊèËɹÇÕÛÒ²ÊǺÏÀíµÄÒÅ´«±íÐÍ£¬ËäÈ»ÔÚ¶Ô¹ÇÖÊÊèËɹÇÕۺ͹ÇÃܶÈÕý³£ÈËȺ»ùÒòÐÍÏà¹Ø·ÖÎöÖв¢Î´·¢ÏÖÓÐÏÔÖø²îÒ죬µ«¸Ã×éCT»ùÒòÐ͹ÇÕÛ·¢ÉúÂÊÔ¶´óÓÚCCÐÍ¡£²»Í¬Í³¼Æ½á¹ûµÄ²îÒì¿ÉÄÜÓëͳ¼Æ·½·¨µÄ²»Í¬¼°Ñù±¾Á¿´óСÓйء£±¾ÊÔÑé½á¹ûÌáʾ£¬ÓбØÒª¶Ôɽ¶«°ëµººº×åÅ®ÐÔ½øÐиü´ó¹æÄ£µÄÑо¿ÒÔ½øÒ»²½Ã÷È·½µ¸ÆËØÊÜÌåAlu-¢ñ»ùÒò¶à̬ÐÔÓë¹ÇÃܶȼ°¹ÇÖÊÊèËÉÐÔ¹ÇÕ۵ĹØÏµ¡£ÎªÁÙ´²ÔçÆÚɸѡ¹ÇÖÊÊèËÉ»ò¹ÇÕ۵ĸßΣÈËȺÌṩÒÅ´«Ñ§ÒÀ¾Ý£¬ÀûÓÚÔçÆÚµÄÓÐЧ·ÀÖΡ£
ÒѾ·¢±íµÄÒÅ´«Ñ§Ñо¿½á¹û²»Ò»Ö£¬ÆäÔÒò¿ÉÄÜÊǾ¡¹ÜºîѡλµãµÄ¹ØÁª·ÖÎö¾ßÓкÜÇ¿µÄͳ¼Æ¹¦Ð§£¬µ«Ò×µ¼Ö¼ÙÒõÐԺͼÙÑôÐÔ½á¹û¡£½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐԵķֲ¼¡¢»ùÒòµÄ±í´ï¼°¶Ô¹ÇÃܶȵÄ×÷ÓÃÊÜÖÖ×å¡¢Éú»î»·¾³¡¢Ñо¿·½·¨¼°Ñù±¾Á¿´óСµÈÒòËØµÄÓ°Ïì¡£Òò´Ë£¬½µ¸ÆËØ»ùÒò¶à̬ÐÔÓë¹ÇÖÊÊèËÉÏ໥¹ØÏµ»¹ÐèÒª½øÐжàÖÐÐÄ¡¢´óÑù±¾µÄÑо¿£¬²¢×ۺϿ¼ÂÇÖî¶àÒòËØµÄÐͬ×÷Óá£
4 ²Î¿¼ÎÄÏ×
1 Kanis JA£¬Melton LJ 3rd£¬Christiansen C£¬et al. The diagnosis of osteoporosis. J Bone Miner Res 1994£»9(8)£º1137-1141
2 Morrison NA£¬Qi JC£¬Tokita A£¬et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994£»367(6460)£º284-287
3 Ralston SH£¬Uitterlinden AG£¬Brandi ML£¬et al. Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes£ºthe GENOMOS study. PLoS Med 2006£»3£¨4£©£ºe90
4 Koay MA£¬Woon PY£¬Zhang Y£¬et al. Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res 2004£»19£¨10£©£º1619-1627
5 Idris AL£¬van¡¯t Hof RJ£¬Greig IR£¬et al. Regulation of bone mass£¬bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005£»11(7)£º774-779
6 Karsak M£¬Cohen-Solal M£¬Freudenberg J£¬et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005£»14(22)£º3389-3396
7 Findlay DM£¬Sexton PM. Calcitonin. Growth Factors 2004£»22(4)£º217-224
8 Wolfe LA 3rd£¬Fling ME£¬Xue Z£¬et al.In vitro characterization of a human calcitonin receptor gene polymorphism. Mutat Res 2003£»522(1-2)£º93-105
9 Nakamura M£¬Zhang ZQ£¬Shan L£¬et al. Allelic variants of human calcitonin receptor in the Japanese population. Hum Genet 1997£»99(1)£º38-41
10 Masi L£¬Becherini L£¬Gennari L£¬et al. Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. Biochem Biophys Res Commun 1998£»245(2)£º622-626
11 Tsai FJ£¬Chen WC£¬Chen HY£¬et al. The ALUI calcitonin receptor gene polymorphism (TT) is associated with low bone mineral density and susceptibility to osteoporosis in postmenopausal women. Gynecol Obstet Invest 2003£»55(2)£º82-87
12 Bandres E£¬Pombo I£¬Gonzalez-Huarriz M£¬et al. Association between bone mineral density and polymorphisms of the VDR£¬ERalpha£¬COL1A1 and CTR genes in Spanish postmenopausal women. J Endocrinol Invest 2005£»28(4)£º312-321
13 Drews K£¬Seremak-Mrozikiewicz A£¬Barkowiak-Wieczorek J£¬et al. Genetic polymorphism of the calcitonin receptor gene and bone mineral density in Polish population of postmenopausal women. Ginekol Pol 2005£»76(8)£º612-618
14 Zhang ZL,Meng XW£¬Zhou XY£¬et al. Zhonghua Neifenmi Daixie Zazhi 2002£»18(2)£º90-94
ÕÂÕñÁÖ£¬ÃÏѸÎᣬÖÜѧ壬µÈ.±±¾©µØÇøºº×帾ŮάÉúËØDÊÜÌå»ùÒòºÍ½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓë¹ÇÃܶȵĹØÏµ[J].ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾£¬2002£¬18(2)£º90-94
15 Cui XW£¬Hu YG£¬Zheng HJ£¬et al. Zhonghua Laonian Yixue Zazhi 2002£»21(4)£º297
´ÞѧÎÄ£¬ºúÓйȣ¬Ö£ºì¾ü£¬µÈ.½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓë¾ø¾ºó¸¾Å®¹ÇÖÊÊèËɵÄÏà¹ØÐÔ̽ÌÖ[J].ÖлªÀÏÄêҽѧÔÓÖ¾£¬2002£¬21(4)£º297
16 Wang Q, Ge BF, Yin Y, et al. Zhongguo Linchuang Kangfu 2004;8(27)£º5901-5903
Íõçù£¬¸ð±¦·á£¬ÒóÓ¨£¬µÈ.²Ø×帾Ů½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐԺ͹ÇÖÊÊèËɵÄÏà¹ØÐÔ[J].ÖйúÁÙ´²¿µ¸´£¬2004£¬8(27)£º5901-5903
17 Xu MH£¬Liu HD£¬Tong XX. Zhongguo Kangfu Lilun Yu Shijian 2005£»11£¨4£©£º247-249
ÐíÃ÷»Û£¬ÁõºÍæ·£¬Ù¡ÏþÐñ.VDRºÍCTR»ùÒò¶à̬ÐÔÓëºÓ±±ºº×帾Ů¹ÇÃܶȹØÏµÑо¿[J].Öйú¿µ¸´ÀíÂÛÓëʵ¼ù£¬2005£¬11£¨4£©£º247-249
18 Li DF£¬Wu W£¬Cai XZ£¬et al. Hunan Yufang Yixue 2005£»31£¨6£©£º12-14£¬19
Àî¶«·ç£¬ÎâÎÄ£¬²ÌÑ©Õ䣬µÈ.½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓë¹ãÖݵØÇø¾ø¾ºó¸¾Å®¹ÇÃܶȹØÏµÑо¿[J].»ªÄÏÔ¤·Àҽѧ£¬2005£¬31£¨6£©£º12-14£¬19
19 Li DF£¬Cai XZ£¬Yang YH£¬et al. Zhongshan Daxue Xuebao£ºYixue Kexue Ban 2006£»27£¨4£©£º410-413
Àî¶«·ç£¬²ÌÑ©Õ䣬ÑîÑàºì£¬µÈ.½µ¸ÆËØÊÜÌå»ùÒò¶à̬ÐÔÓëÀÏÄêÄÐÐÔ¹ÇÃܶȹØÏµ[J].ÖÐɽ´óѧѧ±¨£ºÒ½Ñ§¿ÆÑ§°æ£¬2006£¬27£¨4£©£º410-413
|